<bill session="116" type="s" number="4199" updated="2023-01-11T13:45:40Z">
  <state datetime="2020-07-02">REFERRED</state>
  <status>
    <introduced datetime="2020-07-02"/>
  </status>
  <introduced datetime="2020-07-02"/>
  <titles>
    <title type="display">Prescription Drug Pricing Reduction Act of 2020</title>
    <title type="short" as="introduced">Prescription Drug Pricing Reduction Act of 2020</title>
    <title type="official" as="introduced">A bill to amend titles XI, XVIII, and XIX of the Social Security Act to lower prescription drug prices in the Medicare and Medicaid programs, to improve transparency related to pharmaceutical prices and transactions, to lower patients' out-of-pocket costs, and to ensure accountability to taxpayers, and for other purposes.</title>
  </titles>
  <sponsor bioguide_id="G000386"/>
  <cosponsors>
    <cosponsor bioguide_id="B001310" joined="2020-07-02"/>
    <cosponsor bioguide_id="C001075" joined="2020-07-02"/>
    <cosponsor bioguide_id="C001035" joined="2020-07-02"/>
    <cosponsor bioguide_id="D000618" joined="2020-07-02"/>
    <cosponsor bioguide_id="E000295" joined="2020-07-02"/>
    <cosponsor bioguide_id="H001079" joined="2020-07-02"/>
    <cosponsor bioguide_id="M001197" joined="2020-07-02"/>
    <cosponsor bioguide_id="M001153" joined="2020-07-02"/>
    <cosponsor bioguide_id="P000449" joined="2020-07-02"/>
    <cosponsor bioguide_id="S001198" joined="2020-09-10"/>
  </cosponsors>
  <actions>
    <action datetime="2020-07-02">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2020-07-02" state="REFERRED">
      <text>Read twice and referred to the Committee on Finance.</text>
      <reference ref="CR S4228" label="Sponsor introductory remarks on measure"/>
    </action>
  </actions>
  <committees>
    <committee code="SSFI" name="Senate Finance" subcommittee="" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill session="116" type="h" number="1264" relation="unknown"/>
    <bill session="116" type="h" number="1781" relation="unknown"/>
    <bill session="116" type="h" number="3029" relation="unknown"/>
    <bill session="116" type="h" number="4629" relation="unknown"/>
    <bill session="116" type="h" number="4649" relation="unknown"/>
    <bill session="116" type="h" number="5281" relation="unknown"/>
    <bill session="116" type="h" number="5882" relation="unknown"/>
    <bill session="116" type="s" number="801" relation="unknown"/>
    <bill session="116" type="s" number="1505" relation="unknown"/>
    <bill session="116" type="s" number="1999" relation="unknown"/>
    <bill session="116" type="s" number="2543" relation="unknown"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Accounting and auditing"/>
    <term name="Administrative law and regulatory procedures"/>
    <term name="Advisory bodies"/>
    <term name="Appropriations"/>
    <term name="Congressional oversight"/>
    <term name="Department of Health and Human Services"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Drug therapy"/>
    <term name="Emergency medical services and trauma care"/>
    <term name="Fraud offenses and financial crimes"/>
    <term name="Genetics"/>
    <term name="Government information and archives"/>
    <term name="Government studies and investigations"/>
    <term name="Health care costs and insurance"/>
    <term name="Health care coverage and access"/>
    <term name="Health care quality"/>
    <term name="Health information and medical records"/>
    <term name="Health programs administration and funding"/>
    <term name="Health technology, devices, supplies"/>
    <term name="Home and outpatient care"/>
    <term name="Hospital care"/>
    <term name="Indian social and development programs"/>
    <term name="Infectious and parasitic diseases"/>
    <term name="Inflation and prices"/>
    <term name="Intergovernmental relations"/>
    <term name="Manufacturing"/>
    <term name="Medicaid"/>
    <term name="Medical ethics"/>
    <term name="Medicare"/>
    <term name="Minority health"/>
    <term name="Poverty and welfare assistance"/>
    <term name="Prescription drugs"/>
    <term name="Public contracts and procurement"/>
    <term name="Public participation and lobbying"/>
    <term name="Retail and wholesale trades"/>
    <term name="Social work, volunteer service, charitable organizations"/>
    <term name="State and local government operations"/>
  </subjects>
  <amendments/>
  <summary date="2020-08-31T14:59:55Z" status="Introduced in Senate">Prescription Drug Pricing Reduction Act of 2020

This bill alters several programs and requirements relating to the prices of prescription drugs under Medicare and Medicaid.

Among other things, the bill

 requires drug manufacturers to issue rebates to the Centers for Medicare &amp; Medicaid Services (CMS) for certain drugs covered under Medicare for which the average manufacturer price increases faster than inflation; requires drug manufacturers to issue rebates to the CMS for discarded amounts of certain single-dose drugs covered under Medicare, based on information reported by providers; reduces the annual out-of-pocket spending threshold, and eliminates beneficiary cost-sharing above this threshold, under the Medicare prescription drug benefit; requires the CMS to publish certain information, as reported by pharmacy benefit managers (PBMs), relating to drug discounts and rebates, and payments between PBMs, health plans, and pharmacies; requires pass-through pricing models, and prohibits spread-pricing, for payment arrangements with PBMs under Medicaid; and increases the maximum rebate payable by drug manufacturers under the Medicaid Drug Rebate Program.</summary>
</bill>
